Traded Mar 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 4, 2026 · Filed Mar 5, 2026
The CEO of Visteon sold $1.68M of Visteon shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,679,335
Shares × reported transaction price
13 days after results of Feb 19, 2026, 50 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.4% | −1.5% | +0.1% |
| 30 days | +0.5% | −2.0% | +2.5% |
| 90 days | +34.8% | +12.6% | +22.2% |
| 180 days | +12.6% | +13.8% | −1.2% |
Past results only. Not a forecast.
Traded Mar 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 15 · filed 2 days later
Routine share withholding; mechanical by default.
Traded Mar 15 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.